These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29662106)

  • 21. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
    Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
    Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.
    Lee MS; Liu CY; Su L; Christiani DC
    Lung Cancer; 2015 Jul; 89(1):8-12. PubMed ID: 26001533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ERCC1 and ERCC2 variants predict survival in gastric cancer patients.
    Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY
    PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA Repair Gene Polymorphisms in Relation to Non-Small Cell Lung Cancer Survival.
    Su Y; Zhang H; Xu F; Kong J; Yu H; Qian B
    Cell Physiol Biochem; 2015; 36(4):1419-29. PubMed ID: 26159902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer.
    Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX
    Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.
    Zhang L; Ma W; Li Y; Wu J; Shi GY
    Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
    Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
    J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
    Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC.
    Cui LH; Yu Z; Zhang TT; Shin MH; Kim HN; Choi JS
    Pharmacogenomics; 2011 Jun; 12(6):797-808. PubMed ID: 21605004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
    Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J
    Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roles of XRCC1/XPD/ERCC1 Polymorphisms in Predicting Prognosis of Hepatocellular Carcinoma in Patients Receiving Transcatheter Arterial Chemoembolization.
    Wang XC; Wang F; Quan QQ
    Genet Test Mol Biomarkers; 2016 Apr; 20(4):176-84. PubMed ID: 26918371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer.
    Zheng DL; Tang GD; Chen YN; Zhang T; Qin MB
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.
    Zhao X; Zhang Z; Yuan Y; Yuan X
    Tumour Biol; 2014 Aug; 35(8):8335-41. PubMed ID: 24859833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.
    Tan LM; Qiu CF; Zhu T; Jin YX; Li X; Yin JY; Zhang W; Zhou HH; Liu ZQ
    Sci Rep; 2017 Jul; 7(1):5593. PubMed ID: 28717179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
    Mlak R; Krawczyk P; Ramlau R; Kalinka-Warzocha E; Wasylecka-Morawiec M; Wojas-Krawczyk K; Kucharczyk T; Homa I; Kozioł P; Ciesielka M; Chudziak D; Milanowski J
    Oncol Rep; 2013 Nov; 30(5):2385-98. PubMed ID: 23982437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
    Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N
    BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.